Freenome is an early cancer detection company developing blood-based screening tests to detect cancer when it is most treatable. The company's Personalized Cancer Detection approach combines multiomics, artificial intelligence and machine learning to develop screening tests tailored to the biology of individual cancers and the needs of specific patient populations. Freenome's first commercial-stage test, SimpleScreen(TM) CRC, is an FDA-approved blood-based screening test for colorectal cancer in adults 45 and older who are at average risk for the disease. Beyond colorectal cancer, Freenome continues to advance a pipeline of non-invasive single- and multi-cancer screening tests across additional cancer indications, in pursuit of its mission to make cancer screening more accessible and increase participation.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $0.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 139.47 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -2.70% |
| Return on Assets (Trailing 12 Months) | -0.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.20 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.54 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.06 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 107.45M |
| Free Float | 83.74M |
| Market Capitalization | $1.41B |
| Average Volume (Last 20 Days) | 0.70M |
| Beta (Past 60 Months) | 0.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.06% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |